Table 3 Summary of efficacy measures

From: Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation

Outcome

Controls (N = 52)

Mut-positive (N = 26)

P-value

Overall survival (mo)

  

0.0467

    Median

18.8

24.6

–

Real-world progression free survival (mo)

  

0.0068

    Median

6.9

10.1

–

Overall response rate—no. (%)a

8 (21)

14 (58)

0.0022

    Complete response

1

0

–

    Partial response

7

14

–

    Stable disease

24

5

–

    Progressive disease

7

5

–

Disease control rate—no. (%)b

42 (81)

21 (81)

 > 0.99

Overall response rate by regimen - no. with response/no. evaluable (%)a

 

–

 

    FOLFIRINOX

8/29 (28)

6/10 (60)

–

    FOLFOX

0 (0)

4/8 (50)

–

    Gemcitabine cisplatin

0 (0)

4/6 (67)

–

  1. Response criteria according to RECIST (response evaluation criteria in solid tumours) v1.1
  2. Patients in the control group (n = 13) and mut-positive group (n = 2) without measurable disease at baseline were excluded from overall response rate analysis. The two patients in the mut-positive group without measurable were treated with FOLFOX and were thus excluded from the subset analysis of overall response to FOLFOX
  3. aThe overall response rate was defined as the percentage of patients that achieved complete response or partial response
  4. bThe disease control rate was defined as the percentage of patients that achieved complete response, partial response or stable disease. Patients without measurable disease at baseline were included in the DCR analysis. Patients were defined as having SD or PD based on evaluation of non-target lesions
Back to article page